Glox Therapeutics appoints Dr. Michael Murray as Chair and Dr. Nel Moore as Scientific Advisory Board Member
Glox Therapeutics announced the appointment of Dr. Michael Murray as Chair of the Board.
He will work with the team to accelerate the company’s growth and help guide the commercialization of its technology. The company has also expanded its scientific advisory board (SAB), adding Dr. Nel Moore to support the development of its novel engineered protein bacteriocins to target drug-resistant pathogenic bacteria and help overcome antimicrobial resistance (AMR).
Dr. Michael Murray is the Principal at Murray International Partners who has led multiple high-value international deals in the life sciences sector. He has nearly 30 years’ experience in senior and interim management roles at several biotech/pharma companies, including Metallobio, Porton Biopharma, EnteroBiotix, Sosei Heptares, and Amura Therapeutics, as well as an international commercial consultancy practice. He teaches commercial IP strategy on the Novo Nordisk Fellowship MBA in BioMedical Design program (Denmark) and has delivered training to over 1,200 individuals in the commercialization of technical innovations since 2015. Dr Murray is also a Member of The Royal Society Industry College, an Entrepreneur in Residence at the University of Sheffield, where he was a Royal Society Entrepreneur in Residence from 2019–2022, a Mentor at Cambridge Enterprise and, from 2017 until last year, was a Member of both the Research Strategy Board and the Commercialization Committee of Coeliac UK. He is also a Registered Technology Transfer Professional and a Member of the International Technology Transfer Network (China). Dr Murray holds a PhD in Molecular Cell Biology from the University of Leicester.
Dr. Nel Moore has gained vast expertise in global drug discovery, development and commercialization in the areas of immunology, oncology and anti-infectives throughout her 21-year career in the pharmaceutical industry. Formerly, Vice President of Antibiotics Development at AstraZeneca, Dr Moore led the late-stage development, global regulatory submission and approval of Zavicefta/Avycaz for the treatment of multidrug-resistant bacterial infections. She went on to build and lead AstraZeneca’s antibiotics development organization, supporting four antibiotics in various stages of development and commercialization, before its divestment to Pfizer. Since 2018, she has been supporting biotech companies with strategic planning, implementation and execution of business plans, and fundraising in her role as a senior R&D consultant at FWEast and non-executive director. She is currently, also an Independent Council Member at Aston University and Executive Chair/CEO of CHAIN Biotechnology. Dr Moore holds a PhD in Biochemistry from the University of Birmingham and currently sits on several CARB-X Advisory Boards.
